BioSpace News Archive

Following the launch of QUVIVIQ™ CIV on May 2, Idorsia Pharmaceuticals, U.S. Inc. announced that the first wave of patients has been prescribed the product through a pharmacy services provider.

aTyr Pharma, Inc. announced that the Compensation Committee of aTyr’s Board of Directors has granted four employees nonstatutory stock options to purchase an aggregate of 113,400 shares of its common stock, each with an exercise price of $3.48 per share, which is equal to the closing price of aTyr’s common stock on the Nasdaq Capital Market on May 10, 2022, the effective date of the grants.

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022.

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022.

Anika Therapeutics, Inc. announced that on May 2, 2022, Anika granted non-statutory stock options covering an aggregate of 13,091 shares of common stock at a per share exercise price of $21.61.

On May 12, the US Food and Drug Administration (FDA) granted approval to oral edaravone (RADICAVA ORS) for the treatment of amyotrophic lateral sclerosis (ALS).

The U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection, Eli Lilly and Company’s (NYSE: LLY) new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Artelo Biosciences, Inc. announced that Gregory D. Gorgas, Chief Executive Officer of Artelo has been invited to present at the Spring Into Action - Best Ideas Virtual Investor Conference, which is being held virtually May 16th - 20th, 2022.

Edesa Biotech, Inc. reported financial results for the three and six months ended March 31, 2022 and provided an update on its business.

Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), today announced that it has raised approximately $5.1 million from new and existing investors in a private placement of its shares.